Abstract: A process is disclosed for continuously treating a solubilized protein solution containing a protein unfolded to some degree, in a small volume continuous flow reactor, to obtain the protein in a conformation exhibiting the protein's characteristic biological activity by continuously diluting out the solubilizing agent, while continuously withdrawing the refolded protein. The continuous process may be carried out using deionized water as a diluent, rather than buffer solutions.
Abstract: Modified human tissue plasminogen activators, the DNA sequences coding on expression for them and methods of making them in hosts transformed with those DNA sequences. The single chain form of these modified human t-PAs, t-PA (Lys 277.fwdarw.X), has a longer half life than the single chain form of native, or recombinant, t-PA, yet, in the two chain form these modified t-PAs have substantially the same affinity for fibrin and substantially the same activity as the two chain form of native, or recombinant, t-PA.
Abstract: Improved expression vectors for amplifying expression of DNA sequence encoding a desired polypeptide beyond that expected by the vector copy number. The vector contains a DNA sequence within the replicon of the vector encoding RNA I and the primer RNA for initiation of DNA replication and their regulatory regions, said DNA sequence having an AT to GC mutuation at position 3029 in the two strands of pBR322; a promoter of RNA I or primer RNA and a restriction site for insertion of a DNA sequence encoding a desired polypeptide into the vector and operatively linking the DNA sequence to the expression control sequence. The AT to GC mutation causes an increase in the vector copy number and further amplifies the expression of the desired polypeptide operatively linked to the RNA I or primer RNA promoter beyond that expected by the copy number increase.
Abstract: Recombinant DNA molecules and hosts transformed with them which produce polypeptides displaying HBV antigenicity and genes coding therefor and methods of making and using these molecules, hosts, genes and polypeptides. The recombinant DNA molecules of this invention are characterized by structural genes that code for at least one polypeptide displaying HBV antigenicity. In appropriate hosts these recombinant DNA molecules permit the production and identification of genes and polypeptides characteristic of HBV antigenicity and their use in compositions and methods for detecting HBV virus infections in humans and stimulating the production of antibodies against this infection.
Abstract: DNA sequences, recombinant DNA molecules and processes for producing bovine growth hormone-like polypeptides in high yield and the novel polypeptides produced thereby. These polypeptides are useful in improving the rate of growth of and meat production and quality in cattle.
Abstract: Small peptides that display the specificity of FMD viral antigens. The peptides are useful in compositions and methods for the protection of animals for at least some time from FMD viral infections. The peptides of this invention may be prepared by conventional synthetic methods, recombinant DNA technology or a combination of the two. They may also be modified in composition and conformation to improve further their specific antigenic properties.
Abstract: Polypeptides displaying the antigenicity of hepatitis B virus e antigens, DNA sequences coding for those polypeptides, antibodies to those polypeptides and methods of producing and using those polypeptides, antibodies and DNA sequences. The polypeptides and antibodies of this invention are characterized by their use in compositions and methods for detecting hepatitis B virus infective carriers and in evaluating the course of HBV-related active liver disease.
Abstract: Recombinant DNA molecules and hosts transformed with them which produce polypeptides displaying a biological or immunological activity of human interferon, the gene coding for these polypeptides and methods of making and using these molecules, hosts, genes and polypeptides. The recombinant DNA molecules are characterized by structural genes that code for a polypeptide displaying a biological or immulogical activity of human interferon. In appropriate hosts these molecules permit the production and identification of genes and polypeptides displaying a biological or immunological activity of human interferon and their use in antiviral and antitumor or anticancer agents.